BioSyent Declares Second Quarter 2023 Dividend

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) —  BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an ‘eligible dividend’ for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 12,091,919 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Staff

Recent Posts

Glytec Software Wins “Best Computerized Decision Support Solution” in 2025 MedTech Breakthrough Awards Program

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies…

4 hours ago

TrustCommerce, a Sphere Company, Wins MedTech Breakthrough Award for Payment Innovation

Healthcare financial technology company wins for Cloud Payments solution   CHICAGO, May 8, 2025 /PRNewswire/…

4 hours ago

Amavita Heart and Vascular Health Achieves Two Prestigious IAOCR Certifications

MIAMI, May 8, 2025 /PRNewswire/ -- Amavita Heart and Vascular Research Services LLC the research…

4 hours ago

Covera Health Expands Radiology Centers of Excellence to Include Prostate MRI, Enhancing Nation’s Leading Imaging Quality Program

Significant expansion of Covera's proven COE platform launching in 2026; provider applications now open, with…

4 hours ago

Reimagining the Cold Chain: Artyc PBC Introduces Medstow 5L to Power a New Era of Healthcare Logistics

Designed for hospitals, clinical trial sites, and home-care teams, the Medstow 5L Intercampus delivers precise,…

4 hours ago